



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C7
Serial No: 10/006,130 Group Art Unit: 1647
Filed: December 6, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "^insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.



Napoleone Ferrara, Ph.D.

10/6/04

Date

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date

James Pan, Ph.D.

Date

Austin Gurney, Ph.D.

Date

Colin K. Watanabe

Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C7
Serial No: 10/006,130 Group Art Unit: 1647
Filed: December 6, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.


5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "^insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ.ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date





Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date

James Pan, Ph.D.

Date

Austin Gurney, Ph.D.

Date

Colin K. Watanabe

Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C7
Serial No: 10/006,130 Group Art Unit: 1647
Filed: December 6, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.


13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ.ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date

Andrey Goddard, Ph.D.

Date



Paul J. Godowski, Ph.D.

10/05/01

Date

James Pan, Ph.D.

Date

Austin Gurney, Ph.D.

Date

Colin K. Watanabe

Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C7
Serial No: 10/006,130 Group Art Unit: 1647
Filed: December 6, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "^insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date

James Pan, Ph.D.

Date



Austin Gurney, Ph.D.

Date


10/5/04

Colin K. Watanabe

Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C7
Serial No: 10/006,130 Group Art Unit: 1647
Filed: December 6, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date

Audrey Goddard, Ph.D.


Date

Paul J. Godowski, Ph.D.

Date



James Pan, Ph.D.



Date

Oct 08/04

Austin Gurney, Ph.D.


Date

Colin K. Watanabe

Date

William I. Wood, Ph.D.

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C7
Serial No: 10/006,130 Group Art Unit: 1647
Filed: December 6, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "^insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.


Date

James Pan, Ph.D.


Date

Austin Gurney, Ph.D.

Date



Colin K. Watanabe



Date

William I. Wood, Ph.D.

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Baker et al. Docket No: 39780-2830P1C7
Serial No: 10/006,130 Group Art Unit: 1647
Filed: December 6, 2001 Examiner: Rachel K. Hunnicutt
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF NAPOLEONE FERRARA, Ph.D.,
AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
AUSTIN GURNEY, Ph.D., JAMES PAN, Ph.D., COLIN K. WATANABE and
WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Napoleone Ferrara, Ph.D., Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., James Pan, Ph.D., Colin K. Watanabe and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by U.S. Patent Publication No. 2003/0096951 (Jacobs *et al.*, publication date May 22, 2003 and effective filing date August 14, 1998).
3. The polypeptide designated as PRO1244 (SEQ ID NO:130) claimed in the above-identified application in the United States was sequenced and cloned prior to August 14, 1998.
4. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, Ph.D., was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA that encoded PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.

5. At the time the PRO1244 polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, Ph.D., was, and still is, responsible for overseeing the sequencing of novel polypeptides, including the PRO1244 polypeptide (SEQ ID NO:130) claimed in the above-identified application.
6. A cDNA clone, referred to as DNA64883-1526 in the above-identified application, was identified as encoding the PRO1244 polypeptide.
7. The full length of the cDNA clone is shown in Figure 73 of the above-identified application. The full-length cDNA sequence has 2213 nucleotide residues. The full length of the PRO1244 peptide encoded by DNA64883-1526 is shown in Figure 74 of the above-identified application. The full-length PRO1244 polypeptide has 335 amino acid residues.
8. Copies of the pages from the GSeqEdit database which report the cloning and sequencing data for the PRO1244 polypeptide sequence and its encoding nucleic acid sequence are attached to this declaration (with the dates redacted) as Exhibit A.
9. The GSeqEdit report shows the full-length nucleic acid sequence for DNA-64883-1526 (identified as "DNA-64883") and the full-length PRO1244 polypeptide encoded by DNA 64883. Both the DNA-64883 and the PRO1244 polypeptide sequences were obtained prior to August 14, 1998.
10. The DNA-64883 sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 129 disclosed in the above-identified application.
11. The beginning of the cDNA sequence corresponding to SEQ ID NO: 129 in the above-identified application is shown on page 1 of the GSeqEdit database report, and the location of the first nucleotide is marked with "insert starts here" and an arrow. The location of the last nucleotide corresponding to SEQ ID NO: 129 is shown on page 11 and is marked with an arrow.
12. The amino acid sequence shown in the GSeqEdit report is identical to that of SEQ ID NO: 130 disclosed in the above-identified application.

13. The first 26 amino acid residues of the PRO1244 polypeptide (SEQ ID NO:130) encoded by the cDNA (DNA-64883) are also shown on page 1 of the GSeqEdit report and the remaining 309 residues appear on pages 2-6 of the report.
14. All activities listed under paragraphs 4-13 were completed prior to August 14, 1998. (See Exhibit A).
15. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Napoleone Ferrara, Ph.D.

Date

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date

James Pan, Ph.D.

Date

Austin Gurney, Ph.D.

Date

Colin K. Watanabe

Date



William I. Wood, Ph.D.



Date

> [REDACTED]
 >DNA64883 [Full]
 >510 Sites [All Sites]
 > [REDACTED] DNA64883 wlv GSeqEdit
 > [REDACTED] DNA64883 zemln GSeqEdit
 > [REDACTED] DNA64883 goddarda GSeqEdit
 > [REDACTED] DNA64883 sheldens GSeqEdit
 >HBN64883.seq, sequenced at ABI/ACGT by Peter Ma and Ellison Chen
 >human ortholog of implantation-associated protein - Rattus

mulI		nlaIII
tagI		mslI
xhoI	thai	styI
cllI	fnuDII/mvnI	ncol
smlI	hinfI acII	dsai
paer7I mwoI	tseI bstUI[M.hai-]	tseI
tsp509I[M.ecoRI-]	fnu4HI/bsofI	btgI/bstDSI
ecoRI	avaI[M.tagI-]	bstXI
apoI mwoI bseRI	nlaIII hhaI/cfoI	bavI
1 CGGAATTCGG CTCGAGAGC GAACATGGCA GCGCGTGGC GGTTTGGTG TGTCTGTGTG ACCAATGTTGG TGGCGCTGCT CATCGTTTGC GACGTTCCCT	bsmAI maeIII	hhaI/cfoI
GCCCTTAAGCC GAGCTCCTCG CTGTACCGT CGCGCAACCG CCAAAACCAC ACAGAGACAC TGGTACCACC ACCGCGACGA GTAGCAAACG CTGCAAGGCA	haeII	hpy99I mnlI
1	M A A R W R F W C V S V T M V V A L L I V C D V P S	

^insert starts here
 ^MET

mlI

alwNI(dcm-)

alw26I/bsmAI

bsaXI

hpy188I

mspAII/pspBII

bsmAI

alul

pvuII

101 CAGCCTCTGC CCAAGAAG AAGAGATG TGTATCTGA AAGGTTAGT CAGCTGATG AATGACTTA CAAAGACT GTAATAAGAA TGAATGAGA

GTGAGACG GGTTCCTTC TTCCTCTACC ACAATAGCT TTTCATCA GTGACTACC TTACCTGAT GTTCTGGA CATATCTCT ACTTACCTCT
27 A S A Q R K K E M V L S E K V S Q L M E W T N K R P V I R M N G D

tspRI

bst4CI/hpyCH4III cac8I

btsI

ahdI/eam1105I cac8I

hpy99I

tsp509I

nlaiII

hpyCH4V tspRI

hpyCH4V al

201 CAAGTTCGT CGCCTTGTGA AAGCCACC GAGAAATTAC TCCGTTATCG TCATGTTTAC TCCTCTCCA CTGATAGAC AGTGTCTGT TTGCAAGCAA
GTCAAGGCA GCGAACACT TTCGGGCTG CTCTTTAATG AGCAATAGC AGTACAAGTG ACGAGAGTT GACGTATCTG TCACACAGCA AACGTTCTGT
60 K F R R L V K A P P R N Y S V I V M F T A L Q L H R Q C V V C K Q

scrFI[dcn-]
 pspGI
 mvaI
 ecorII[dcn-]
 dsaV[dcn-]
 bstNI
 bssKI[dcn-]
 apyI[dcn+]
 sau3AI
 mboI/ndeII[dam-]
 dpmII[dam-]
 dpmI[dam+]
 alwI[dam-]
 bstYI/xhoII
 alwNI[dcn-]
 alw26I/bsmAI
 tsp509I[M.ecorI-]
 ecorI pflMI[dcn-]
 apoI bslI[dcn-]
 mboII hpy188III
 301 GCTGATGAAG AATTCAGAT CCTGGCAAC TCCTGGCGAT ACTCCAGTGC ATTACCAAC AGGATATTTT TTGCCATGGT GGATTTTGAT GAAGGCTCTG
 CGACTACTTC TTAAGTCTA GGACCGTTG AGACCGCTA TGAAGTCACG TAAGTGGTTG TCCTATAAAA AACGTACCA CCTAAACTA CTCCGAGAC
 93 A D E E F Q I L A N S W R Y S S A F T N R I F F A M V D F D E G S D
 apyI[dcn+]
 bsmI/gsuI[dcn-]
 bsaJI
 hpy18
 hpyCH4V
 hpy18
 nlaIII
 styI
 ncoI
 dsai
 btgl/bstDSI
 hpy18

tsp5091[M.ecoRI-]

ecori

hpyCH4V

sfani

apoi

econI

hpy188I

nlaiII aluI

bsII

bsII

hphI

ndel

maeiII acII

401 ATGTAATTCA GATGCTAAC ATGAATTCAG CTCCACTTT CATCACTTT CCTGCAAAAG GGAACCCAA ACCGGGTGAT ACAATAGAGT TACAGGTGCG
TACATAAAGT CTACGATTTG TACTTAAGTC GAGGTGAAA GTAGTGAAG GAGCGTTTTC CCTTGGGTT TGCCCACTA TGTATACTCA ATGTCCACGC
127 Y F Q M L N M N S A P T F I N F P A K G K P K R G D T Y E L Q V R

ddel[M.aluI-]

bspcNI

mspi

saui3AI

celII/espi

hpaII mboI/ndeII[dam-]

blpI/bpu1102I scrFI[M.hpaII-]

aluI

ncII

dpnII[dam-]

pvuII

dsav

dpnI[dam+]

mspAII/nsbII

bskI alwI[dam-]

spsI

tsp509I

avaiI bsII

501 GGGTTTTC GGTGACGAGA TTGCCCCGCTG GATGCCCGAC AGACTGATG TCAATATTAG AGTGATTAGA CCCCCAAAT ATGCTGCTCC CCTATGCTTG
CCCAAAAGT CGACTGCTCT AACGGGCCAC CTAGCGGCTG TCTGACTAC AGTATAATC TCATAATCT GGGGTTTAA TAGACACAG GGAATACAAC
160 G F S A E Q I A R W I A D R T D V N I R V I R P P N Y A G P L M L

tagI

aluI

sfuI

tseI

bstBI

fokI

bsICl

tsp509I

tru9I

bscFI

bvII

baeI

mboII mboII

apoi

mseI

bsrI

mwoI hpyCH4V

601 GGATTGCTTT TGGCTGTAT TGGGACCTT GGTATCTTC GAAGAATAA TATGAATTT CTCTTAATA AAAGTGAAG GGTCTTGCA GCTTGTGTT
CCTAACGAAA ACCGACATA ACCACTGAA CACATAGAG CTCTTCAIT ATACCTTAA GAGAAATTA TTTGACCTAC CCGAAACGT CGAAACGAAA
193 G L L L A V I G G L V Y L R R S N M E F L F N K T G W A F A A L C F

bsmFI
 sau96I
 nlaIV
 avaiI
 bpmI/gsuI[dcM-1]
 aluI hpy188I mseI ecoO109I/draII
 trp9I ppuMI
 bsri csp6I
 tspRI scaI
 tsp509I
 1001 ATGGCTACCC ATACAGCTT CTGATGAGT AAAAAGTCC CAGAGATATA TAGACACTGG AGTACTGGA ATTGAANAAC GAAAATCGTG TGTGTTGAA
 TACCGATGGG TATGTCGAAA GACTACTCAA TTTTTCAGG GTCTCTATAT ATCTGTGACC TCATGACCCT TAACITTTG CTTTACGAC ACACAACTT
 327 G Y P Y S F L M S O

trp9I
 mseI trp9I
 ahaIII/draI
 swaI mseI mseI mboII
 bsmI
 mboII hpyCH4V
 mboII
 swaI mseI mseI mboII
 1101 AAGAAGATG CACTTGAT ATTGTGAT ACCCTTTTT TTCAGTGAT TTAATAGCT AATCATTTAA CCAAGAAGA TGTGTAGTCC CTTAACAAGC
 TTCCTCTAC GTGAACATA TAAACATTA TGAAGAAAA AAGTCACTA AATTATCAA TTAGTAATTT GGTTCCTCT ACACATCAGG GAATTGTTG

mnlI
 ddeI
 bspCNI
 hpy188I
 mnlI
 hpy188I
 tsp509I mseI earI/ksp632I
 1201 AATCCTCTGT CAAATCTGA GGTATTGAA AATAATTATC CTCTTAACCT TCTCTGCCA GTGAACCTTA TGAACATTT AATTAGTAC AATTAGTAT
 TTAGAGACA GTTTAGACT CCATAACTT TTATTAATG GAGAATTGA AGAGAAGGT CACTTGAAT ACCTTGTAA TTAATCATG TTAATTCATA

trp9I
 mseI
 hpaI
 psiI tsp509I
 aluI
 hincII/hindII hpy188I
 bsII
 1301 ATTATAAAA TTGTAAACT ACTACTTGT TTAGTAGA ACAAGCTCA AAACACTTT AGTAACTTG GTCACTGAT TTTATATTGC CTTATCCAAA
 TAAATTTTT AACATTTGA TGATGAACA AATCAATCT TGTTCGAGT TTTGATGAAA TCAATGAAC CAGTAGACTA AATATPACG GAATAGGTTT
 GSegeedit, DNA64883 [Full], page 6

tth1111/aspi

plei

pflfi

mlyi

hlnfi

bpmi/gsu(dcm-)

hlnpi ddei

bseri mli

hlnpi ddei

bsmai bsmi

1601 AGCAAGACAG TTGTTCTCC TCCTCCTGC ATATTCTCA CTGCCCTCA GCCTGAGTGA TAGAGTGA CTCCTCTCA AAAAAGTA TCCTTAATA
TCGTTCTGTC AACAAAGAG AGAGGAGAG TATAAGAT GAGCGAGGT CGGACTCACT ATCTCACTCT GAGACAGAGT TTTTTCAT AGAGATTAT

tru9i

tsp45i

msei

tfii

hphl

tsp509i

hpal

xmi

hlnfi

tru9i maeiii

psii

sml

hincii/hindii

asp700

hpy188i

ddei

msei bsteii

1701 CAGATTATA ATTTCCTT GAGTATGCTG TTAACCTT TGTATTAGA AAGATTGAG ATTCATTCA TCCTCTTAGT TTTCCTTTAA GGAGACCAT
GTCCTAATAT TAAAGACGAA CTCATACCAC AATTGATGA ACATAAATCT TTCCTAAGTC TAAGTAAGT AGAGGATCA AAAGAAAT CCACGGGTA

dde

ddei(m.alu-)

maeiii

haeiii/pali

tsp45i

rsai

alul

tspri

nlaaii

tsp509i

maeiii

csp6i

1801 CTGTGATAA AATATAGCT AGTGCTAAA TCACTGTAAC TTATACATCG CCTAAATGT TTCTACAAAT TAGAGTTGT CACTTAATCC ATTGTACCT
GACACTAATT TTATATCGAA TCACGATTT AGTCACATTG AATATGACC GGATTTTACA AAGATGTTA ATCTCAACA GTGAATAGG TAAACATGGA

msci/bali[dcn-]

aei[dcn-]

scrFI[dcn-]

pspGI

mval

ecorII[dcn-]

dsav[dcn-]

bstNI

bsmAI bssKI[dcn-]

taqI foki cfrI nlaIII

bsmAI

hpy188III bsaI bstFSI haeIII/palI

esp3I

mli hpy188III apyI[dcn+] hphI

bsmBI

tsps09I

nlaIV

2001 GAGGTCAGGA GTTCGAGACC ATCTGGGCA ACATGTTGAA ACCCGCTCTC TACTAAAT ATAAATTA GCTGGGTGTG GTGGCAGAG CCTGTATCC
CTCCAGTCTT CAAGCTCTGG TAGGACCGGT TGTACCACTT TGGGCAAGAG ATGATTTT TAATTTTAT CGACCAACAC CACGCTCTC GGACATTAGG

scrFI[dcn-]

pspGI

mval

ecorII[dcn-]

tsprI dsav[dcn-]

sa3AI btsI bstNI

mboI/ndelI[dcn-] bssKI[dcn-]

dpnII[dcn-] hpyCH4V apyI[dcn+]

dpnI[dcn+] bsgI bpmI/gsuI[dcn-]

2101 CAGCTACACA GGAGGCTGAG GCACGAGAAT CACTTGAAT CAGGAGATGG AGTTTCACT GAGCCGAGAT CACGCCACTG CACTCCAGCC TGGCAACAGA
GTGATGTGT CCTCCGACTC CGTGTCTTA GTGAACTGA GTCTCTACC TCCAAAGTCA CTGGGCTCTA GTGGGTGAC GTGAGTGG ACCGTTCT

GSegeEdit, DNA64883 [Full], page 11